Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06375512 · ClinicalTrials.gov registry record · Phase 1
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
A Phase 1 study of Herpes Zoster, sponsored by Shenzhen Shenxin Biotechnology Co..
- Active
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT06375512: Active Phase 1 study of Herpes Zoster, sponsored by Shenzhen Shenxin Biotechnology Co..
NCT06375512 is a Phase 1 study of Herpes Zoster that is active but no longer recruiting, run by Shenzhen Shenxin Biotechnology Co.. The registered enrollment target is 150 participants, below the 2,164-participant average among 16 other Herpes Zoster trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06375512, a Phase 1 study of Herpes Zoster, is active but no longer recruiting, sponsored by Shenzhen Shenxin Biotechnology Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of age
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Shingrix
- BIOLOGICAL HZ Vaccine (IN001)
Study Locations (3)
Florida
- CenExel - Hollywood
New South Wales
- Emeritus Research Pty Ltd - Sydney
Victoria
- Emeritus Research Pty Ltd - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-07-05 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What the registry record for NCT06375512 still lists
NCT06375512 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 2,164-participant average among 16 other Herpes Zoster trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06375512 reports a single indexed study location in Florida, New South Wales, Victoria.
Frequently Asked Questions
What is clinical trial NCT06375512 about?
NCT06375512 is a clinical study titled "A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants". The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of age
What is the current status of trial NCT06375512?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2024-07-05. Estimated completion is 2026-06.
What conditions does trial NCT06375512 study?
This clinical trial studies the following conditions: Herpes Zoster.
What interventions are being tested in trial NCT06375512?
The interventions under investigation include: Placebo (BIOLOGICAL), Shingrix (BIOLOGICAL), HZ Vaccine (IN001) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06375512?
This trial is sponsored by Shenzhen Shenxin Biotechnology Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06375512 being conducted?
This trial has 3 study locations across Florida, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06375512's enrollment target sits among peer trials
150 13th of 16 higher than 4 of 16 other Herpes Zoster trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Herpes Zoster trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ACTIVE NOT RECRUITING · Phase 1
-
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
COMPLETED · Phase 1
-
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
COMPLETED · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI